Homology modelling, virtual screening and molecular dynamics of the MARK3 KA1 domain for cancer drug design (2011)
- Authors:
- Autor USP: SILVA, CARLOS HENRIQUE TOMICH DE PAULA DA - FCFRP
- Unidade: FCFRP
- DOI: 10.1080/08927022.2011.589052
- Subjects: NEOPLASIAS; QUÍMICA FARMACÊUTICA; PLANEJAMENTO DE FÁRMACOS; MODELAGEM MOLECULAR; HOMOLOGIA
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Molecular Simulations
- ISSN: 0892-7022
- Volume/Número/Paginação/Ano: v. 37, n. 14, p. 1186-1206, 2011
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
SEMIGHINI, Evandro P. e TAFT, Carlton A. e SILVA, Carlos Henrique Tomich de Paula da. Homology modelling, virtual screening and molecular dynamics of the MARK3 KA1 domain for cancer drug design. Molecular Simulations, v. 37, n. 14, p. 1186-1206, 2011Tradução . . Disponível em: https://doi.org/10.1080/08927022.2011.589052. Acesso em: 24 abr. 2024. -
APA
Semighini, E. P., Taft, C. A., & Silva, C. H. T. de P. da. (2011). Homology modelling, virtual screening and molecular dynamics of the MARK3 KA1 domain for cancer drug design. Molecular Simulations, 37( 14), 1186-1206. doi:10.1080/08927022.2011.589052 -
NLM
Semighini EP, Taft CA, Silva CHT de P da. Homology modelling, virtual screening and molecular dynamics of the MARK3 KA1 domain for cancer drug design [Internet]. Molecular Simulations. 2011 ; 37( 14): 1186-1206.[citado 2024 abr. 24 ] Available from: https://doi.org/10.1080/08927022.2011.589052 -
Vancouver
Semighini EP, Taft CA, Silva CHT de P da. Homology modelling, virtual screening and molecular dynamics of the MARK3 KA1 domain for cancer drug design [Internet]. Molecular Simulations. 2011 ; 37( 14): 1186-1206.[citado 2024 abr. 24 ] Available from: https://doi.org/10.1080/08927022.2011.589052 - Química computacional no planejamento de candidatos a quimioterápicos
- Planejamento racional de inibidores de enzimas-alvo aplicado a diferentes doenças: modelagem, síntese, bioquímica e QSAR
- RNA interference in drug discovery
- Sequence and transcriptional study of HNRPK pseudogenes, and expression and molecular modeling analysis of hnRNP K isoforms
- Use of virtual screening, flexible docking, and molecular interaction fields to design novel HMG-CoA reductase inhibitors for the treatment of hypercholesterolemia
- Identification of novel chemical entities for Adenosine receptor type 2A using molecular modeling approaches
- Computer-aided drug design and ADMET predictions for identification and evaluation of novel potential farnesyltransferase
- General aspects of lead finding and optimization in drug discovery
- Molecular dynamics, density functional theory, pharmacophore modeling, molecular interaction fields and ADME/tox investigation of novel bioactive compounds interacting with CDK2 surfaces
- Pharmacophore-based drug design of novel potential tau ligands for Alzheimer's disease treatment
Informações sobre o DOI: 10.1080/08927022.2011.589052 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
